Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 126 are a BUY (72.83%), 45 are a HOLD (26.01%), 2 are a SELL (1.16%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 54.21% that have a potential upside of 29.97% achieved within 195 days.
Judah Frommer’s has documented 319 price targets and ratings displayed on 30 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on FIVE, Five Below at 17-Jul-2024.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$75
$5.94 (8.60%)
$75
4 days ago
(20-Dec-2024)
8/30 (26.67%)
$5.94 (8.60%)
105
Buy
$100
$30.94 (44.80%)
$120
18 days ago
(06-Dec-2024)
5/11 (45.45%)
$26.97 (36.93%)
659
Hold
$76
$6.94 (10.05%)
$64
19 days ago
(05-Dec-2024)
4/10 (40%)
$3.11 (4.27%)
170
Hold
$75
$5.94 (8.60%)
$65
19 days ago
(05-Dec-2024)
24/26 (92.31%)
$2.11 (2.89%)
206
Buy
$83
$13.94 (20.19%)
$79
19 days ago
(05-Dec-2024)
26/36 (72.22%)
$10.11 (13.87%)
144
Which stock is Judah Frommer is most bullish on?
What Year was the first public recommendation made by Judah Frommer?